Amicus Therapeutics Inc

Amicus Therapeutics — FY2021 Earnings Presentation

24 slides from Amicus Therapeutics's earnings presentation, Feb 24, 2022

  1. Slide 1: FY21 Financial Results Conference Call & Webcast

    FY21 Financial Results Conference Call & Webcast February 24, 2022 At the Forefront of Therapies for Rare Diseases

  2. Slide 2: Forward-Looking Statements

    2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and

  3. Slide 3: A Rare Company

    3 A Rare Company Patient Dedicated, Rare Disease Biotechnology Company with Sustained Double-Digit Revenue Growth, a Global Commercial Infrastructure, and Late-stage Development Capabilities AT-GAA a Two-Component Therapy under Regulatory Review for Pompe Disease GLOBAL COMMERCIAL ORGANIZATION World

  4. Slide 4: 2021 Strategic Priorities Accomplished: Setting the Stage for a Successful 2022

    2021 Strategic Priorities Accomplished: Setting the Stage for a Successful 2022 1 2 3 4 5 Achieve double-digit Galafold growth and revenue of $300M to $315M Report data from the AT-GAA Phase 3 PROPEL study and complete BLA and MAA filings for regulatory approvals Advance clinical studies, regulatory

  5. Slide 5: Strategic Update

    5 Strategic Update Projected to achieve profitability in 2023 without the need for any further dilutive equity or equity-related financings Focus on core franchises in Fabry disease and Pompe disease through: .. Continued global growth of Galafold .. Approvals and launch of AT-GAA globally .. Invest

  6. Slide 6: 2022 Strategic Priorities to Drive Value

    2022 Strategic Priorities to Drive Value 1 2 3 4 5 Continued double-digit Galafold growth (15-20%) with revenue of $350M to $365M Secure FDA approval and positive CHMP opinion for AT-GAA Initiate successful, rapid launch in U.S. for AT-GAA Advance best-in-class next-generation genetic medicines and

  7. Slide 7: Galafold (migalastat) Continued Growth

    7 Galafold® (migalastat) Continued Growth... … building a leadership position in the treatment of Fabry disease

  8. Slide 8: 2021 Galafold Success

    8 2021 Galafold Success (as of December 31, 2021) Building on Galafold’s Success and Leveraging Leadership Position to Drive Continued Growth Galafold is indicated for adults with a confirmed diagnosis of Fabry Disease and an amenable variant. The most common adverse reactions reported with Galafold

  9. Slide 9: Galafold Quarterly Trends

    9 Galafold Quarterly Trends Growth Remains Strong with Q4 Revenue of $82M and FY2021 Revenue of $306M $67M $71M $66M $77M $79M $82M 3Q20 4Q20 1Q21 2Q21 3Q21 4Q21 Quarterly Galafold Sales .. Expect non-linear quarterly growth to continue due to uneven ordering patterns .. Distribution of Galafold sal

  10. Slide 10: Key Performance Indicators Lay the Groundwork for 2022

    10 Key Performance Indicators Lay the Groundwork for 2022 .. Hybrid business model (virtual/in-person) surpassed pre-COVID physician interactions .. Achieved estimated 49%+ global share of treated amenable patients .. Multiple new markets opened in 2021 with more expected in 2022 .. Global mix of sw

  11. Slide 11: Galafold Growth Opportunity

    11 Penetration of diagnosed untreated population Increase in newborn screening and diagnostic initiatives Strong intellectual property rights Continued penetration into existing markets Expansion into new geographies Broadening of labels Galafold Growth Opportunity $1B Annual Sales Opportunity at Pe

  12. Slide 12: Global Commercial Infrastructure

    12 - 43 countries with approvals - 35 countries reimbursed sales - Presence in 43 countries Experienced Global Commercial Team Global Commercial Infrastructure Highly Leverageable to Ensure Strong Global Launch of AT-GAA Galafold approvals in 40+ countries and commercial sales in 30+ of those today

  13. Slide 13: AT-GAA (cipaglucosidase alfa + miglustat)

    13 AT-GAA (cipaglucosidase alfa + miglustat) … potential to establish a new standard of care for people living with Pompe disease

  14. Slide 14: Pompe Disease Overview

    14 Deficiency of GAA leading to lysosomal glycogen accumulation and cellular dysfunction Age of onset ranges from infancy to adulthood Symptoms include muscle weakness, respiratory failure, and cardiomyopathy Respiratory and cardiac failure are leading causes of morbidity and mortality 5,000 – 10,00

  15. Slide 15: Phase 3 PROPEL Study Results

    15 Phase 3 PROPEL Study Results Endpoints Across Motor Function, Pulmonary Function, Muscle Strength, PROs, and Biomarkers Favored AT-GAA over Alglucosidase Alfa

  16. Slide 16: AT-GAA: Key Takeaways

    16 AT-GAA: Key Takeaways .. Regulatory status update: – U.S. PDUFA date mid 20221 – CHMP opinion late 2022 – Planning for additional regulatory submissions .. Multiple early access mechanisms in place, including in the U.K., Germany, Japan, and others .. 150+ people living with Pompe disease are on

  17. Slide 17: Launch Preparations

    17 Launch Preparations Experienced and Passionate Rare Disease Medical and Commercial Organization Poised for Second Successful Launch Key Strengths Commitment to patient access Clear focus on launch Identification of key Pompe disease centers Development of educational materials Planning Access Edu

  18. Slide 18: Financial & Operational Strategy

    18 Financial & Operational Strategy … maintaining a strong financial outlook

  19. Slide 19: 2021 Select Financial Results

    19 2021 Select Financial Results 2021 Revenue of $306M and Growth Rate of 17% from Global Galafold Sales Dec. 31, 2021 (in thousands, except per share data) Dec. 31, 2020 Product Revenue $305,514 $260,886 Cost of Goods Sold 34,466 31,044 R&D Expense 272,049 308,443 SG&A Expense 192,710 156,407 Chang

  20. Slide 20: Non-GAAP Operating Expense

    20 $412M $416M $407M Guidance: $470M-$485M 2019 2020 2021 2022 2023+ Non-GAAP Operating Expense Non-GAAP Expense Forecasting and Budgeting Historically In-Line with Company Guidance Guidance: $410M-$420M Guidance: $410M-$420M Guidance: $410M-$420M In 2023, Amicus expects non- GAAP operating expense

  21. Slide 21: Financial Outlook and Path to Profitability

    Financial Outlook and Path to Profitability Clear Strategy to Build our Business, Advance our Portfolio, and Achieve Profitability 21 Sustain Galafold Revenue Growth Deliver on Financial Goals Secure Approvals of AT-GAA $306M full-year 2021 revenue, +17% 2022 Galafold revenue guidance of $350M-$365M

  22. Slide 22: Thank You

    Thank You

  23. Slide 23: Appendix

    Appendix

  24. Slide 24: Reconciliation of Non-GAAP Financial Measures

    Appendix Amicus Therapeutics, Inc. Reconciliation of Non-GAAP Financial Measures (in thousands) December 31 2021 2020 2019 Total operating expenses - as reported GAAP 3 477,482 3 476,340 3 464301 Research and development: Share-based compensation 17,340 20,817 17,575 Selling, general and administrat

Amicus Therapeutics — FY2021 Earnings Presentation on 6ix